A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts
Condition: Cutaneous Common Warts
MeSH terms: Warts
Intervention: CLS006 (Furosemide) Topical Gel; Vehicle Topical Gel
Intervention MeSH terms: Furosemide
Phase: Phase 3
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Enrollment: 484.0
Sex: All
Minimum age: 2 Years
Healthy volunteers: No

Summary:

      To evaluate the efficacy and safety of six (6) weeks of once daily application of Furosemide
      Topical Gel 0.125% (CLS006) compared to vehicle in subjects ≥ 2 years of age with nongenital
      cutaneous common warts (verruca vulgaris).
    

Eligibility criteria:

        Inclusion Criteria:

          -  Subjects must have 1 to 6 clearly identifiable common warts located on hands feet
             limbs, and/or trunk

               -  Each wart must measure 3 to 10 mm in their longest dimension (diameter) on the
                  epidermal plane of the skin at baseline visit,

               -  Each wart must be present for at least 4 weeks at the baseline visit,

               -  Plantar, facial, subungual, and common warts in regions of a pre-existing
                  inflammatory condition are excluded. In addition, other warts (e.g., flat,
                  genital) are excluded.

          -  Male or female subjects 2 years of age or older

          -  Females of childbearing potential who are using a highly effective form of birth
             control or females of non-childbearing potential

          -  Negative in-office urine pregnancy test at Screening and Baseline

          -  Subjects free of any clinically significant dermatologic disorder in the treatment
             area

          -  Subjects free of any clinically significant systemic condition which will interfere
             with the study assessments or increase the risk of AEs

          -  Subjects willing to refrain from using other topical products in the treatment area,
             or prohibited medications for the duration of the study

        Exclusion Criteria:

          -  Subjects who have used any wart treatments/therapies, prescription or
             over-the-counter, as follows:

               -  Salicylic acid, cantharidin, sinecatechins (VeregenTM), simple occlusion (e.g.,
                  duct tape), and/or any other over-the-counter wart-removing products in the
                  treatment area within 4 weeks of the Baseline Visit.

               -  Cryotherapy (e.g., treatment with liquid nitrogen), carbon dioxide,
                  electrodessication, laser, surgery, or other forms of mechanical destruction
                  (e.g., emery boards, clippers, debriders, etc.) in the treatment area within 8
                  weeks of the Baseline Visit.

               -  Treatment with immunotherapy (DPCP, DNCB or other), imiquimod,
                  5-fluorouracil,bleomycin, podophyllin or any other wart immunotherapy or
                  treatment (e.g., Candida antigen) designed to stimulate immune response within 12
                  weeks of the Baseline Visit.

          -  Subjects who are immunocompromised.

          -  Subjects who have taken, within 30 days prior to the Baseline visit, or require
             treatment with systemic immunosuppressive or immunomodulatory medication (including
             oral or parenteral corticosteroids) during the course of the study

          -  Subjects who require ongoing treatment with oral or injectable furosemide

          -  Subjects who have used an investigational drug/device within 30 days of the Baseline
             visit

          -  Subjects with known sensitivities to any of the investigational product ingredients
             including furosemide (or other sulfonamides).

          -  Subjects who have a clinically significant abnormality of the cardiovascular, hepatic
             or renal systems.

          -  Subjects with clinically relevant/significant abnormal laboratory results, vital
             signs, ECG, and/or physical findings at Screening and/or Baseline

          -  Subjects with a chronic medical condition or clinically significant abnormal physical
             or laboratory finding(s) that may require the use of a prohibited
             medication/treatment.

          -  Subjects who currently abuse alcohol or drugs or who have a history of chronic alcohol
             or drug abuse within the past year.